News

AddToAny

Google+ Facebook Twitter Twitter

Long Covid – first evidence of inflammatory micro clots

New research indicates that an overload of various inflammatory molecules “trapped” inside insoluble microscopic blood clots could be the cause of some of the lingering symptoms of long COVID.

The finding was made by Professor Resia Pretorius from Stellenbosch University.

She said: “We found high levels of various inflammatory molecules trapped in micro clots present in the blood of individuals with long COVID. Some of the trapped molecules contain clotting proteins such as fibrinogen, as well as alpha(2)-antiplasmin.”

Alpha(2)-antiplasmin is a molecule that prevents the breakdown of blood clots, while fibrinogen is the main clotting protein. Under normal conditions the body’s plasmin–antiplasmin system maintains a fine balance between blood clotting and fibrinolysis.

With high levels of alpha(2)-antiplasmin in the blood of COVID-19 patients and those suffering from long COVID, the body’s ability to break down the clots is significantly inhibited.

Further research is recommended into a regimen of therapies to support clotting and fibrinolytic system function in individuals with lingering long COVID symptoms.

bit.ly/2WFIgRQ

Image credit | Science-Photo-Library

Related Articles

Medical Science Laboratory with Diverse Multi-Ethnic Team of Microbiology Scientists Have Meeting on Developing Drugs, Medicine, Doing Biotechnology Research-CREDIT_istock-1293772951

Equity, diversity and inclusion for all

Jemma Shead, a Senior Biomedical Scientist at Synnovis and IBMS EDI Working Group member, on how and why you should get involved with EDI.

adeno associated virus capsid-Image Credit | Science Photo Library - c0142837

Examining the medical mystery of child hepatitis outbreak

A study has shed light on an unexpected wave of severe acute hepatitis cases in 2022, amid the backdrop of the ongoing global COVID-19 pandemic.

clostridioides difficile bacteria-Image Credit | Science Photo Library - c0016337

Faecal microbiota transplant for C. diff

In the first comprehensive US evidence-based guideline on the use of faecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological Association recommends faecal microbiota transplant (FMT) for most patients with recurrent Clostridioides difficile (C. diff) infection.

pseudomonas aeruginosa bacteria Image-Credit | Science Photo Library - f0381226

Tackling priority pathogen with phages

A new study describes the use of phage therapy to eradicate multidrug-resistant Pseudomonas aeruginosa infections in vivo with important new implications for antibiotic resistance.

Top